Clinical Trial

A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer

Enrolling by Invitation Early Phase 1
View on ClinicalTrials.gov →
Summary
An exploratory clinical study evaluating the safety and efficacy of ACT#001 chimeric antigen receptor T-cell (CAR-T cell) local injection in the treatment of castration-resistant prostate cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-20.
Status change: Not Yet Recruiting → Enrolling by Invitation 2026-05-18
Trial Details
NCT Number NCT07240857
Lead Sponsor Zhejiang University
Collaborators: Orig Stone Biotech(Zhejiang) Co.,Ltd.
Conditions Castration-Resistant Prostate Cancer (CRPC)
Enrollment 18 participants
Start Date 2026-04-12
Primary Completion 2026-10-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-22